AI drug discovery Collaboration opportunities with CPI's AI software for drug discovery and licensing could be extended to pharma and biotech partners seeking to accelerate pipelines for rare and neglected diseases.

AI oncology focus CPI has publicized AI-driven anti-cancer drug development through Can-Fite collaboration; leverage partnerships to propose joint AI model validation, co-development, or milestone-based licensing deals.

SBIR funding leverage With SBIR grant success and NIEHS funding, identify clients or grant-enabled projects that could benefit from CPI’s MegaTox machine learning capabilities and environmental safety analytics to de-risk early-stage programs.

Geographic expansion Recent Raleigh office expansion signals a regional growth strategy; target nearby biotech clusters and government or university collaborations to build software services and consulting engagements.

Commercial software growth Launch of acetylcholinesterase inhibitor prediction software offers a foothold for enterprise licensing, API partnerships, and professional services to pharma and consumer health clients requiring predictive tooling.